(Q79741748)

English

DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates

scientific article published on 16 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Siyuan Shen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Shixia Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

William J Britt

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

16 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

3319-3327

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

The clinical significance of infections with cytomegalovirus strains resistant to antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Encouraging prospects for immunisation against primary cytomegalovirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Analysis of Interstrain Variation in Cytomegalovirus Glycoprotein B Sequences Encoding Neutralization-Related Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

The DNA sequence of the human cytomegalovirus genome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

The human cytomegalovirus UL100 gene encodes the gC-II glycoproteins recognized by group 2 monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Neutralization of cytomegalovirus virions: the role of complement

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

gpUL73 (gN) genomic variants of human cytomegalovirus isolates are clustered into four distinct genotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Mechanism of host cell protection from complement in murine cytomegalovirus (CMV) infection: identification of a CMV-responsive element in the CD46 promoter region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.01.011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17287056%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79741748&oldid=1948997310"